Trials / Completed
CompletedNCT04913532
Hypofractionation With Simultaneous Integrated Boost for Early Breast Cancer
A Phase II Trial of Evaluation of Acute Toxicity in Hypofractionation With Simultaneous Integrated Boost for Early Breast Cancer
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 35 (actual)
- Sponsor
- Capital Medical University · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Simultaneous integrated boost radiotherapy has been investigated in some malignant tumors and appears to be safe and feasible. However, Hypofractionation with simultaneous integrated boost has been investigating in breast cancer. Investigators initiated this phase II prospective trial to analyse acute toxicity of hypofractionation with simultaneous integrated boost in patients with early breast cancer.
Detailed description
Hypofractionated radiotherapy of the breast 15 × 2.70 Gy with simultaneous integrated boost to the tumor bed (total dose within the boost volume 15 × 3.20 Gy)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | Hypofractionation with simultaneous integrated boost | Hypofractionation with simultaneous integrated boost |
Timeline
- Start date
- 2021-06-22
- Primary completion
- 2023-06-30
- Completion
- 2025-07-31
- First posted
- 2021-06-04
- Last updated
- 2026-01-23
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04913532. Inclusion in this directory is not an endorsement.